Micro-X (MX1) Stock Overview
Designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MX1 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Micro-X Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.034 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.035 |
| Beta | -0.62 |
| 1 Month Change | -24.44% |
| 3 Month Change | -40.35% |
| 1 Year Change | -24.44% |
| 3 Year Change | -71.67% |
| 5 Year Change | -89.38% |
| Change since IPO | -94.33% |
Recent News & Updates
MX1: New Finance Leadership Will Support Recall Resolution And Future Upside
Analysts have kept their A$ price target for Micro-X unchanged, citing only slight adjustments to inputs such as the discount rate and future P/E assumptions rather than any material shift in their outlook for the stock. What’s in the News for Micro-X Micro-X initiated a voluntary Class II recall of its Rover Mobile X-ray System, Model/Catalog Numbers MXU-RV35 and MXU-RV71, after the US Food and Drug Administration identified a potential malfunction in the X-ray generator that may render the device inoperable.MX1: Recall Management And New CFO Appointment Will Support Bullish Outlook
Analysts have kept their A$0.15 price target for Micro-X unchanged, with only small tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E, resulting in a steady view of fair value. What's in the News The US Food and Drug Administration has issued a voluntary Class II recall for Micro-X's Rover Mobile X-ray System (Models MXU-RV35 and MXU-RV71), covering 32 units distributed in WA, NJ, CA and Puerto Rico, due to a potential X-ray generator malfunction that may render the device inoperable, source: FDA recall notice via company filing.MX1: Future CFO Appointment Will Support Bullish Outlook Despite Higher Risk Assumptions
Analysts have revised their fair value estimate for Micro-X to A$0.15 from A$0.17, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E. What's in the News Appointment of Peter Dickman as Chief Financial Officer, effective March 30, 2026, bringing more than 20 years of senior finance experience across large listed companies and multiple markets.We're Keeping An Eye On Micro-X's (ASX:MX1) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Recent updates
MX1: New Finance Leadership Will Support Recall Resolution And Future Upside
Analysts have kept their A$ price target for Micro-X unchanged, citing only slight adjustments to inputs such as the discount rate and future P/E assumptions rather than any material shift in their outlook for the stock. What’s in the News for Micro-X Micro-X initiated a voluntary Class II recall of its Rover Mobile X-ray System, Model/Catalog Numbers MXU-RV35 and MXU-RV71, after the US Food and Drug Administration identified a potential malfunction in the X-ray generator that may render the device inoperable.MX1: Recall Management And New CFO Appointment Will Support Bullish Outlook
Analysts have kept their A$0.15 price target for Micro-X unchanged, with only small tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E, resulting in a steady view of fair value. What's in the News The US Food and Drug Administration has issued a voluntary Class II recall for Micro-X's Rover Mobile X-ray System (Models MXU-RV35 and MXU-RV71), covering 32 units distributed in WA, NJ, CA and Puerto Rico, due to a potential X-ray generator malfunction that may render the device inoperable, source: FDA recall notice via company filing.MX1: Future CFO Appointment Will Support Bullish Outlook Despite Higher Risk Assumptions
Analysts have revised their fair value estimate for Micro-X to A$0.15 from A$0.17, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E. What's in the News Appointment of Peter Dickman as Chief Financial Officer, effective March 30, 2026, bringing more than 20 years of senior finance experience across large listed companies and multiple markets.We're Keeping An Eye On Micro-X's (ASX:MX1) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is Micro-X (ASX:MX1) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...NEX Focus Will Advance Mobile X-ray And CT Imaging
Strategic focus on NEX technology and partnerships aim to boost revenue with high-margin medical imaging and baggage scanner products.Slammed 27% Micro-X Limited (ASX:MX1) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Micro-X Limited ( ASX:MX1 ) share price has dived 27% in the last thirty days...Take Care Before Diving Into The Deep End On Micro-X Limited (ASX:MX1)
With a price-to-sales (or "P/S") ratio of 3.1x Micro-X Limited ( ASX:MX1 ) may be sending bullish signals at the...Micro-X Limited (ASX:MX1) Doing What It Can To Lift Shares
There wouldn't be many who think Micro-X Limited's ( ASX:MX1 ) price-to-sales (or "P/S") ratio of 4.4x is worth a...Sentiment Still Eluding Micro-X Limited (ASX:MX1)
With a price-to-sales (or "P/S") ratio of 3.9x Micro-X Limited ( ASX:MX1 ) may be sending bullish signals at the...Is Micro-X (ASX:MX1) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholders May Not Be So Generous With Micro-X Limited's (ASX:MX1) CEO Compensation And Here's Why
Shareholders of Micro-X Limited ( ASX:MX1 ) will have been dismayed by the negative share price return over the last...We Think Micro-X (ASX:MX1) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Here's Why We're Watching Micro-X's (ASX:MX1) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...What We Learned About Micro-X's (ASX:MX1) CEO Pay
Peter Rowland became the CEO of Micro-X Limited ( ASX:MX1 ) in 2014, and we think it's a good time to look at the...What Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?
Every investor in Micro-X Limited ( ASX:MX1 ) should be aware of the most powerful shareholder groups. Insiders often...Have Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...Micro-X Limited's (ASX:MX1) Shift From Loss To Profit
Micro-X Limited (ASX:MX1) is possibly approaching a major achievement in its business, so we would like to shine some...Shareholder Returns
| MX1 | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -8.1% | 3.1% | -1.4% |
| 1Y | -24.4% | -45.3% | 2.2% |
Return vs Industry: MX1 exceeded the Australian Medical Equipment industry which returned -45.3% over the past year.
Return vs Market: MX1 underperformed the Australian Market which returned 2.2% over the past year.
Price Volatility
| MX1 volatility | |
|---|---|
| MX1 Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: MX1 has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MX1's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Kingsley Hall | www.micro-x.com |
Micro-X Limited designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components. It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; Argus, a wide-area scattered projection backscatter and miniaturized high-voltage generator; and space imaging solutions.
Micro-X Limited Fundamentals Summary
| MX1 fundamental statistics | |
|---|---|
| Market cap | AU$25.52m |
| Earnings (TTM) | -AU$11.83m |
| Revenue (TTM) | AU$16.90m |
Is MX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MX1 income statement (TTM) | |
|---|---|
| Revenue | AU$16.90m |
| Cost of Revenue | AU$8.84m |
| Gross Profit | AU$8.06m |
| Other Expenses | AU$19.89m |
| Earnings | -AU$11.83m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 47.70% |
| Net Profit Margin | -70.02% |
| Debt/Equity Ratio | 0% |
How did MX1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 17:21 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Micro-X Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Power | CGS International |
| Scott Power | Morgans Financial Limited |